Related to GSK Pays U.S. Govt $750M for Selling Contaminated and Substandard Drugs

• Tips for Managing Bribery and Corruption Risks
  Operations in emerging markets are particularly liable.
  
• Federal Circuit Holds that Methods of Optimizing Drug Efficacy Are Patentable
  Pending U.S. Supreme Court decision could further transform the standard for patentability of medical diagnostic claims.
  
• Opening Up the Lines of Communication at the Patent Office
  Changes to the count system, which tracks examiners’ workflow, grant them one more hour to conduct interviews.
  
• New Uncertainty Regarding Disclosure of Adverse Effects
  Recent Matrixx Initiatives decision muddies requirements set forth in Carter-Wallace over a decade ago.
  
• Part 1—The U.S. International Trade Commission and Intellectual Property
  Advantages of going to the ITC over U.S. courts include speedy resolutions and remedies that prohibit infringers from the entire U.S. market.
  
• Part 2—Tips for Biotech/Pharma Complainants and Respondents When Going to the ITC
  Going to the ITC provides needed tools like foreign discovery that are not available in a district court.
  
• Sirtuins: Antiaging Medicines or Marketing?
  GSK shelled out $720 million for Sirtris but admits that the new science needs validation.
  
• Examining Both Sides of the Sirtuin Coin
  Jury is still out on whether inhibition and/or activation can treat neurodegenerative disorders.
  
• Court Confirms “Separate” Written Description Requirement
  Decision draws more scrutiny to the validity of broad claims and impacts the decision on when to file an application.
  
• Lupus Drug Development Remains Risky Business
  Research to understand underlying causes is, nonetheless, prompting some interest.